BACKGROUND: Preclinical studies have indicated that BRCA1 functions differentially to modulate the chemosensitivity of cancer cells. PATIENTS AND METHODS: To clarify these findings, BRCA1 expression in primary tumors was evaluated by immunohistochemistry in 50 patients with metastatic breast cancer. RESULTS: BRCA1 expression was absent in 29 (58.0%) out of the 50 breast tumors tested. BRCA1-absent tumors were more frequently progesterone receptor-negative (p=0.019) than BRCA1-present tumors. Taxane-based chemotherapy was administered to 19 patients. Although BRCA1 expression did not relate to the clinical tumor response to taxane-based chemotherapy, time-to-progression (TTP) was significantly shorter in patients with BRCA1-absent tumors than in BRCA1-present tumors (mean+/-SD: 6.5 +/- 4.9 and 14.7 +/- 5.9 months, respectively; p=0.006). The Cox proportional hazard model revealed that BRCA1 absence was an independent predictor of progression (hazard ratio: 3.22; p=0.035). CONCLUSION: These results suggest that the absence of BRCA1 expression is an independent predictor of shorter TTP in advanced breast cancer patients treated with taxane-based chemotherapy.
BACKGROUND: Preclinical studies have indicated that BRCA1 functions differentially to modulate the chemosensitivity of cancer cells. PATIENTS AND METHODS: To clarify these findings, BRCA1 expression in primary tumors was evaluated by immunohistochemistry in 50 patients with metastatic breast cancer. RESULTS:BRCA1 expression was absent in 29 (58.0%) out of the 50 breast tumors tested. BRCA1-absent tumors were more frequently progesterone receptor-negative (p=0.019) than BRCA1-present tumors. Taxane-based chemotherapy was administered to 19 patients. Although BRCA1 expression did not relate to the clinical tumor response to taxane-based chemotherapy, time-to-progression (TTP) was significantly shorter in patients with BRCA1-absent tumors than in BRCA1-present tumors (mean+/-SD: 6.5 +/- 4.9 and 14.7 +/- 5.9 months, respectively; p=0.006). The Cox proportional hazard model revealed that BRCA1 absence was an independent predictor of progression (hazard ratio: 3.22; p=0.035). CONCLUSION: These results suggest that the absence of BRCA1 expression is an independent predictor of shorter TTP in advanced breast cancerpatients treated with taxane-based chemotherapy.
Authors: David J Gallagher; Angel M Cronin; Matthew I Milowsky; Michael J Morris; Jasmine Bhatia; Peter T Scardino; James A Eastham; Kenneth Offit; Mark E Robson Journal: BJU Int Date: 2011-07-14 Impact factor: 5.588
Authors: S Bayraktar; A M Gutierrez-Barrera; H Lin; N Elsayegh; T Tasbas; J K Litton; N K Ibrahim; P K Morrow; M Green; V Valero; D J Booser; G N Hortobagyi; B K Arun Journal: Clin Exp Metastasis Date: 2013-02-01 Impact factor: 5.150
Authors: George E Duran; Yan C Wang; E Brian Francisco; John C Rose; Francisco J Martinez; John Coller; Diana Brassard; Patricia Vrignaud; Branimir I Sikic Journal: Mol Cancer Ther Date: 2014-11-21 Impact factor: 6.261
Authors: J Thomas De Ligio; Aneliya Velkova; Diego A R Zorio; Alvaro N A Monteiro Journal: Anticancer Agents Med Chem Date: 2009-06 Impact factor: 2.505